Liver transplant recipients are at high risk for surgical site infections SSIs Limited data are available on SSI epidemiology following liver transplant procedures LTPs We analyzed data on SSIs from 2015 to 2018 reported to CDC's National Healthcare Safety Network to determine rates, pathogen distribution, and antimicrobial resistance after LTPs and other hepatic, biliary, or pancreatic procedures BILIs LTP and BILI SSI rates were 57 and 59, respectively The odds of SSI after LTP were lower than after BILI adjusted odds ratio = 070, 95 confidence interval 057-085 Among LTP SSIs, 431 were caused by Enterococcus spp, 172 by Candida spp, and 150 by coagulase-negative Staphylococcus spp CNS Percentages of SSIs caused by Enterococcus faecium or CNS were higher after LTPs than BILIs, whereas percentages of SSIs caused by Enterobacteriaceae, Enterococcus faecalis, or viridans streptococci were higher after BILIs Antimicrobial resistance was common in LTP SSI pathogens, including E faecium 694 vancomycin resistant; Escherichia coli 688 fluoroquinolone non-susceptible and 447 extended spectrum cephalosporin [ESC] non-susceptible; and Klebsiella pneumoniae and K oxytoca 394 fluoroquinolone non-susceptible and 545 ESC non-susceptible National LTP SSI pathogen and resistance data can help prioritize studies to determine effective interventions to prevent SSIs and reduce antimicrobial resistance in liver transplant recipients
  Iron overload-induced oxidative stress and transfusion-acquired hepatitis C virus HCV infection are the main reasons of liver damage in beta thalassemia major β-TM
 
  Based on metformin's hepatic benefits in nondiabetic populations, the study aims to investigate the safety and the potential hepatoprotective effect of metformin in HCV-infected β-TM adolescent patients
 
  This was a prospective, randomised, parallel, controlled, open-label study in which 60 HCV-infected β-TM adolescent patients aged 11 to 18years and receiving no antiviral therapy were selected and randomly assigned to treatment or control group in 11 allocation Both groups were receiving β-TM standard-of-care regimen, whereas metformin 500mg, twice daily was added to the treatment group's regimen only Patients were prospectively followed up for 6months with assessment of liver biochemical profile, oxidative stress markers, liver fibrosis, clinical symptom improvement and metformin's adverse effects
 
  Aspartate aminotransferase serum level decreased significantly over time in the treatment group only P=013 However, improvement was not clinically significant and did not attain normality Change in total antioxidant capacity and malondialdehyde serum levels indicated significantly improved oxidative stress status in the treatment group versus significant deterioration in the control group Plt;001 Fibrosis grade improvement was observed in 14 patients in the treatment group versus one improved case in the control group
 
  The use of metformin in HCV-infected β-TM adolescent patients as an adjuvant antioxidant hepatoprotective agent is promising and can improve liver damage
 The use of metformin in HCV-infected β-TM adolescent patients as an adjuvant antioxidant hepatoprotective agent is promising and can improve liver damageTo assess the association of height loss in old age with subsequent risk of hip and any clinical fracture in men late in life while accounting for the competing risk of mortality, we used data from 3491 community-dwelling men mean age 792 years Height loss between baseline and follow-up mean 70 years between examinations was categorized as less then 1 cm referent group, ≥1 to less then 2 cm, ≥2 to less then 3 cm, and ≥3 cm Men were contacted every 4 months after the follow-up examination to ask about fractures confirmed by radiographic reports and ascertain vital status deaths verified by death certificates Competing risk methods were used to estimate absolute probabilities of fracture outcomes by height loss category and calculate adjusted risks of fracture outcomes by height loss During an average of 78 years, 158 45 men experienced a hip fracture and 1414 405 died before experiencing this event The absolute 10-year probability of fracture events accounting for the competing risk of death increased with greater height loss  https//wwwselleckchemcom/products/SP600125html  For example, the hip fracture probability was 27 95 confidence interval [CI] 19-38 among men with height loss less then 1 cm increasing to 116 95 CI 80-160 among men with height loss ≥3 cm After adjustment for demographics, fall history, multimorbidity, baseline height, weight change, and femoral neck bone mineral density and considering competing mortality risk, men with height loss ≥3 cm versus less then 1 cm had a nearly twofold subdistribution hazard ratio [HR] = 194, 95 CI 106-355 higher risk of hip fracture and a 14-fold subdistribution HR = 142, 95 CI 105-191 increased risk of any clinical fracture Height loss ≥3 cm in men during old age was associated with higher subsequent risk of clinical fractures, especially hip fractures, even after accounting for the competing risk of death and traditional skeletal and non-skeletal risk factors © 2021 American Society for Bone and Mineral Research ASBMR
  P-wave duration and P-wave dispersion PWD are thought to be the surrogate marker of devoloping atrial fibrillation AF The main purpose of present study was to investigate the association between presystolic wave PSW, aortic valve sclerosis, and PWD
 
  Patients with sinus rhythm admitted to the cardiology outpatient clinic were consecutively enrolled Maximum Pmax and minimum Pmin P-wave duration and PWD were measured Echocardiography was used to assess the aortic valve morphology and presence of PSW The patients were divided into two groups according to presence or absence of AVSc and PSW
 
  A total of 100 patients were enrolled consecutively Patients with both PSW and AVSc had higher PWD values compared with those without PSW 42±15 vs 65±20 and AVSc 52±21 vs 69±19 The patients were categorized on the basis of median PWD values According to univariate analysis, there was significant association between PWD and presence of PSW P 004, presence of AVS P 011, hypertension P 01 interventricular septal thickness IVST P